Skip to main content

Table 2 Details of surgical intervention and postoperative treatment data including complications and recurrence

From: Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival

  Gastric carcinoma (n = 31) Esophageal carcinoma (n = 17) Total (n = 48)
Type of surgery
 Esophagectomy 1 (3%) 15 (88%) 16 (33%)
 Gastrectomy 30 (97%) 2 (12%) 32 (66%)
 HIPEC 14 (45%) 1 (6%) 15 (31%)
Additional resection
 None 10 (32%) 5 (29%) 15 (31%)
 Peritoneum 16 (51%) 2 (12%) 18 (37%)
 Distant lymph nodes 1 (3%) 3 (18%) 4 (8%)
 Liver 1 (3%) 3 (18%) 4 (8%)
 Adrenal 3 (10%) 0 3 (6%)
 Multivisceral resection 0 4 (24%) 4 (8%)
 Perioperative in-patient stay in days 11 (8–23) 14 (7–94) 12 (7–94)
 Perioperative in intensive care in days 4 (2–11) 5 (3–22) 4 (2–22)
Perioperative complications
 Clavien Dindo 13 (42%) 10 (59%) 23 (48%)
 I/II 9 (29%) 7 (41%) 16 (33%)
 III/IV 3 (10%) 1 (6%) 4 (8%)
 V 1 (3%) 2 (12%) 3 (6%)
Resection margin
 R0 21 (68%) 12 (70%) 33 (69%)
 R1 (primary tumor) 3 (9%) 1 (6%) 4 (8%)
 R2 (non-resected metastases) 7 (22%) 4 (23%) 11 (23%)
Postoperative residual tumor
 Local 3 (10%) 1 (6%) 4 (8%)
 Peritoneal carcinomatosis 3 (10%) 2 (12%) 5 (10%)
 Lymph nodes 1 (3%) 2 (12%) 3 (6%)
 Distant metastasis 3 (10%) 0 3 (6%)
 Recurrence 12 (39%) 7 (41%) 19 (40%)
 Time of recurrence after surgery in months* 5,5 (1–15) 6,5 (1–10) 6 (1–15)
Type of recurrence
 Local 1 (8%) 0 1 (5%)
 Local and distant 2 (17%) 2 (29%) 4 (21%)
 Peritoneal carcinomatosis 4 (33%) 1 (14%) 5 (26%)
 Hepatic metastasis 3 (25%) 3 (43%) 6 (32%)
 Other type of metastasis 1 (8%) 1 (14%) 2 (11%)